Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption ...

The Technology Adoption Program successfully tested the ability of the Bridgewater Smart Factory to automate, lower costs and ...

Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...

Cellares’ Cell Shuttle performed all unit operations in an automated manner, including cell isolation, enrichment, gene ...

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

Schematic Overview of the Development of a Bespoke Islet-specific Microenvironment Using Bioprinting Technology to Enhance ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Topas Therapeutics today announced the publication of data highlighting the ability of its proprietary antigen-coupled ...